Monitoring Frequency for Ferritin and TSAT in Patients Receiving ESAs

Standard Monitoring Schedule

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend evaluating ferritin and TSAT at least every 3 months in patients receiving ESA therapy, regardless of dialysis status, to serve as the foundation for decisions to start or continue iron supplementation 1, 2
The 3-month interval applies to all CKD patients on ESA therapy, allowing clinicians to detect functional iron deficiency and prevent iron overload 1

When initiating ESA therapy, monthly monitoring is recommended during the initial treatment phase to assess iron adequacy 3
The KDIGO guidelines suggest testing more frequently when increasing ESA dose to assess iron adequacy 1, 2
After blood loss events, recheck iron parameters to detect depletion, and following IV iron administration, monitor response after completing a course of IV iron 1

The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines recommended monitoring TSAT and ferritin at least once every 3 months in hemodialysis patients to optimize erythropoiesis by adjusting iron dosing 4, 5, 6
Monitoring TSAT and ferritin at least every 3 months allows clinicians to detect functional iron deficiency before it impairs ESA response, prevent iron overload, adjust iron supplementation, and optimize ESA dosing requirements 1

The American Journal of Kidney Diseases recommends maintaining TSAT >20% and ferritin >100 ng/mL in non-dialysis and peritoneal dialysis CKD patients, and TSAT >20% and ferritin >200 ng/mL in hemodialysis patients 3, 5
There is insufficient evidence to recommend IV iron if ferritin >500 ng/mL, according to the American Journal of Kidney Diseases 3